| Literature DB >> 32497745 |
Marco Meloni1, Valentina Izzo2, Laura Giurato2, Roberto Gandini2, Luigi Uccioli2.
Abstract
AIM: To define the outcomes of persons with diabetes and foot ulcers (DFUs) managed through a specific triage pathway during the COVID-19 crisis.Entities:
Keywords: Amputation; COVID-19; Diabetes; Diabetic foot ulcers; Mortality
Mesh:
Year: 2020 PMID: 32497745 PMCID: PMC7263238 DOI: 10.1016/j.diabres.2020.108245
Source DB: PubMed Journal: Diabetes Res Clin Pract ISSN: 0168-8227 Impact factor: 5.602
The proposed new triage pathway for managing DFUs patients according to ulcer features and comorbidities.
| Grading of ulcer’ severity | Number of comorbidities | Management |
|---|---|---|
Wet gangrene Abscess Necrotizing fasciitis Acute limb ischemia Fever Sepsis | Action required regardless of the number of comorbidities. | Urgent hospitalization |
Mild infection Chronic limb ischemia Deep to tendons, muscles or bone ulcers | ≥ 3 comorbidities | First visit and follow-up by telemedicine. In the case of ulcer impairment clinical re-evaluation should be performed. |
Mild infection Chronic limb ischemia Deep to tendons, muscles or bone ulcers | ≤ 2 comorbidities | First visit and regular follow-up, according to individual circumstance |
Superficial Not infected Not ischemic | Action required regardless of the number of comorbidities. | First visit and follow-up by telemedicine |
| Action required regardless of the number of comorbidities. | Follow-up by telemedicine |
Baseline demographic and clinical characteristics of the study group.
| Variables | Values |
|---|---|
| Age | 69.9 ± 14.2 |
| Sex (male) | 89 (58.9%) |
| Diabetes type (2) | 138 (91.4%) |
| Diabetes duration (years) | 18.9 ± 12.2 |
| HbA1c (mmol/mol) (%) | (59 ± 8)(7.5 ± 1) |
| Hypertension | 144 (95.4%) |
| Dyslipidemia | 120 (79.5%) |
| Ischemic heart disease | 58 (38.4%) |
| Heart failure | 40 (26.5%) |
| End-stage-renal-disease | 22 (14.6%) |
| Chronic pulmunary obstructive disease | 22 (14.6%) |
Characteristics of foot ulcerations at first clinical evaluation.
| Variables | Values |
|---|---|
| Neuro-ischemic/ischemic ulcers | 54.7% |
| Infection | 64% |
| Size (>5 cm2) | 66.6% |
| Depth (to muscle, tendons and/or bone) | 79.7% |
| Gangrene | 42% |
Fig. 1Severity of DFUs according to fast-track pathway classification.
Number of concomitant comorbidities.
| Number of comorbidities | Values (n) (%) |
|---|---|
| 1 comorbidity | 6 (4%) |
| 2 comorbidities | 26 (17.2%) |
| 3 comorbidities | 49 (32.4) |
| 4 comorbidities | 28 (18.5%) |
| 5 comorbidities | 22 (14.6%) |
| 6 comorbidities | 15 (9.9%) |
| 7 comorbidities | 5 (3.3%) |
Fig. 2Rate of concomitant co-diseases.
Outcomes of the study group.
| Outcomes | N (%) |
|---|---|
| Healing | 41/151 (31.8%) |
| Major amputation | 3/151 (2%) |
| Deaths | 3/151(2%) |
| Foot ulceration impairment in telemedicine patients | 3/45 (6.6%) |
| COVID-19 infection | 1/151 (0.7%) |